WALTHAM, Mass. / Oct 14, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability driven investments and other efforts aimed at advancing science and human health responsibly.
“Early in our sustainability journey, we established ambitious, but realistic goals to guide our progress in efforts that would positively impact people and the planet. In just one year since our inaugural Impact Report, our team has eclipsed our waste reduction goal and continues to make considerable advances across other key areas,” said Prahlad Singh, president and chief executive officer at Revvity. “Looking ahead, we’re confident in our ability to navigate complexity and deliver results as we create a lasting, meaningful impact for our customers, colleagues, shareholders and communities.”
The 2025 Impact Report highlights the Company’s progress in advancing its responsible business philosophy and operations, with key achievements including:
To learn more about Revvity’s commitments and progress visit esg.revvity.com.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$96.15 |
| Daily Change: | -2.75 -2.78 |
| Daily Volume: | 1,405,450 |
| Market Cap: | US$11.160B |
October 27, 2025 September 29, 2025 September 22, 2025 August 18, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load